The CLL-17 study, comparing continuous ibrutinib to time-limited therapies, showed overlapping efficacy. Its main impact wasn't declaring a winner, but affirming that oncologists can base treatment decisions on patient preference for continuous vs. fixed-duration therapy, knowing outcomes will be similar.

The next wave of CLL research is moving beyond a standard one-year fixed duration. Ongoing studies now use Minimal Residual Disease (MRD) results to tailor treatment length, personalizing care by potentially shortening, extending, or adding therapies based on a patient's individual depth of response.

Although continuous BTK inhibitors have the most prospective data for high-risk CLL (17p/TP53 mutations), some highly motivated patients still opt for fixed-duration treatment. This requires a detailed conversation where clinicians must explain the trade-off: achieving a treatment-free period may come at the cost of needing second-line therapy sooner.

The CLL17 study revealed a significant difference in undetectable Minimal Residual Disease (UMRD) rates between treatment arms, yet Progression-Free Survival (PFS) curves were not statistically different. This challenges the assumption that UMRD can consistently serve as a direct proxy for long-term survival outcomes in all contexts.

Despite strong single-agent trial results, experts believe the field is shifting away from continuous monotherapy. The most significant future impact for pirtobrutinib will likely be as a backbone of fixed-duration combination therapies with drugs like venetoclax, aiming for deeper remissions without indefinite treatment.

The UK FLAIR trial demonstrated for the first time that a time-limited regimen (ibrutinib-venetoclax), guided by MRD to a median duration of 27 months, achieved superior progression-free and overall survival compared to continuous ibrutinib therapy in frontline CLL.

The CLL17 study reveals that continuous ibrutinib, fixed-duration venetoclax/obinutuzumab, and fixed-duration venetoclax/ibrutinib all yield identical progression-free survival rates at three years. This finding empowers clinicians to choose a strategy based on patient preference (continuous vs. fixed-duration) without compromising near-term efficacy.

For older CLL patients, stopping acalabrutinib after 18 months results in relapse within a year for half of them. However, their overall survival remains identical to those who continue treatment, suggesting a "drug holiday" is a safe option for managing side effects or patient preference without long-term detriment.

The CLL17 trial revealed a counterintuitive finding: unfit patients had worse outcomes on continuous ibrutinib, likely due to toxicity-related discontinuations. The logistically harder venetoclax-obinutuzumab fixed-duration regimen produced equal efficacy in both fit and unfit patients, making it a better choice for the less fit.